BING Z CARTER to Disease Models, Animal
This is a "connection" page, showing publications BING Z CARTER has written about Disease Models, Animal.
Connection Strength
0.226
-
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model. Haematologica. 2020 05; 105(5):1274-1284.
Score: 0.066
-
Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 15; 24(10):2417-2429.
Score: 0.059
-
Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther. 2017 06; 16(6):1133-1144.
Score: 0.056
-
Bcl-2 inhibition combined with PPARa activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia. Cell Death Dis. 2023 08 29; 14(8):573.
Score: 0.022
-
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 11 26; 3(22):3661-3673.
Score: 0.017
-
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst. 2006 Aug 02; 98(15):1068-77.
Score: 0.007